Breaking News Instant updates and real-time market news.

ADRO

Aduro Biotech

$13.95

0.1 (0.72%)

08:01
11/21/16
11/21
08:01
11/21/16
08:01

Aduro Biotech announces LADD partial clinical hold lifted

Aduro Biotech announced that the FDA has lifted the partial clinical hold placed on its clinical trials evaluating the LADD immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies. In agreement with the FDA, Aduro's LADD-based clinical trial protocols have been modified to include extended patient surveillance, to exclude patients with certain prosthetic devices that are not easily removed, and to add guidance to administer prophylactic antibiotics following LADD-based treatment for patients who may receive immune-suppressive treatments.

ADRO Aduro Biotech
$13.95

0.1 (0.72%)

05/16/16
ROTH
05/16/16
NO CHANGE
Target $22
ROTH
Buy
Roth cuts Aduro target to $22, takes off Focus List
Roth Capital analyst Joseph Pantginis lowered his price target for Aduro Biotech to $22 from $46 and removed the stock from his firm's Focus List after the company announced that its Phase IIb study did not meet its overall survival endpoint in third-line and greater pancreatic cancer. The analyst keeps a Buy rating on Aduro, however, seeing upside from future pipeline contributions and signed partnerships with its Listeria-based LADD technology. The stock is down 18%, or $1.89, to $8.80 in afternoon trading.
05/17/16
ADAM
05/17/16
NO CHANGE
Target $30
ADAM
Buy
Aduro Biotech price target lowered to $30 from $43 at Canaccord
Canaccord lowered its price target on Aduro Biotech to $30 from $43 after its pancreatic cancer drug missed its primary endpoints in a Phase IIb study. The firm said there is potential for its STELLAR drug trial to still succeed, but lowered the probability and thus the price target. Canaccord maintained its Buy rating on Aduro Biotech shares.
05/17/16
JANY
05/17/16
NO CHANGE
Target $22
JANY
Buy
Aduro study failure has limited read-through to Advaxis, says Janney Capital
Janney Capital analyst Roy Buchanan said the failure of a trial Aduro Biotech's (ADRO) listeria-based immunotherapy candidate in advanced pancreatic cancer should have limited read-through to Advaxis' (ADXS) own listeria-based immunotherapy program. The lead indications for Advaxis, including HPV-driven cervical cancer, have good rationale that the HPV is causative, Buchanan tells investors. The analyst keeps a Buy rating and $22 fair value estimate on Advaxis shares.
10/25/16
ROTH
10/25/16
NO CHANGE
Target $20
ROTH
Buy
Aduro Biotech LADD platform takes another perception knock, says Roth Capital
Roth Capital analyst Joseph Pantginis says Aduro Biotech's LADD platform took another perception knock with a second case of a patient's treatment port testing positive for listeria. While there was no listeriosis/systemic impact to the patient and it resolved quickly, a partial clinical hold has been put in place with no new enrollment in LADD studies until protocols are modified with the FDA for increased surveillance. The analyst says his confidence remains high on the LADD platform and reiterates a Buy rating on the stock. Nonetheless, he lowered his price target on the shares to $20 from $22.

TODAY'S FREE FLY STORIES

GE

General Electric

$18.76

-0.26 (-1.37%)

08:43
01/16/18
01/16
08:43
01/16/18
08:43
Hot Stocks
GE CEO 'deeply disappointed' in magnitude of charge in insurance portfolio »

GE CEO John Flannery said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

GSL

Global Ship Lease

$1.18

-0.01 (-0.84%)

08:43
01/16/18
01/16
08:43
01/16/18
08:43
Hot Stocks
Global Ship Lease announces extension of charter with CMA CGM »

Global Ship Lease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

08:42
01/16/18
01/16
08:42
01/16/18
08:42
Hot Stocks
Qualcomm sees 'serviceable addressable market' of $150B by 2020 »

Qualcomm (QCOM) stated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

, TSRO

Tesaro

$69.59

-2.07 (-2.89%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Recommendations
Heron Therapeutics, Tesaro analyst commentary  »

Cinvanti competitor…

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

TSRO

Tesaro

$69.59

-2.07 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, AAPL

Apple

$177.09

1.81 (1.03%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Hot Stocks
Qualcomm announces plan for new $1B cost reduction program »

As previously reported,…

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

AAPL

Apple

$177.09

1.81 (1.03%)

AVGO

Broadcom

$264.29

0.79 (0.30%)

NXPI

NXP Semiconductors

$119.58

0.33 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 06

    Mar

AAPL

Apple

$177.09

1.81 (1.03%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Periodicals
House Republicans call on Apple to address iPhone slowdowns, Reuters reports »

Four U.S. House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

CIEN

Ciena

$21.94

0.06 (0.27%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Upgrade
Ciena rating change  »

Ciena upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Upgrade
Adtran rating change  »

Adtran upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

FNSR

Finisar

$22.74

0.48 (2.16%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Downgrade
Finisar rating change  »

Finisar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, AVGO

Broadcom

$264.29

0.79 (0.30%)

08:38
01/16/18
01/16
08:38
01/16/18
08:38
Earnings
Qualcomm 'firmly committed' to FY19 adjusted EPS target of $6.75-$7.50 »

As previously reported,…

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

AVGO

Broadcom

$264.29

0.79 (0.30%)

NXPI

NXP Semiconductors

$119.58

0.33 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MTN

Vail Resorts

$222.31

3.37 (1.54%)

08:38
01/16/18
01/16
08:38
01/16/18
08:38
Recommendations
Vail Resorts analyst commentary  »

Vail Resorts price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$42.81

-0.01 (-0.02%)

, INTC

Intel

$43.24

-0.17 (-0.39%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Recommendations
Micron, Intel analyst commentary  »

Micron pullback a buying…

MU

Micron

$42.81

-0.01 (-0.02%)

INTC

Intel

$43.24

-0.17 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Mar

ATTU

Attunity

$6.71

-0.061 (-0.90%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
Attunity wins $1.2M in additional business with Fortune 100 company »

Attunity announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OTIV

On Track Innovations

$1.37

-0.01 (-0.72%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
On Track Innovations announces additional order of 10,000 cashless readers »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$39.37

-0.39 (-0.98%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
Synchrony reports December charge-off rate 4.94% vs. 5.03% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

F

Ford

$13.23

0.07 (0.53%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Periodicals
Ford sees savings in 'every part' of business, FT reports »

Ford will have to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

MDXG

MiMedx

$13.86

-0.08 (-0.57%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
MiMedx: First patients enrolled in Phase 3 clinical trial of AmnioFix Injectable »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
Ultra Clean sees Q1 revenue up from Q4 »

The company said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LBCC

Long Blockchain Corp.

$5.02

-0.48 (-8.73%)

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Hot Stocks
Breaking Hot Stocks news story on Long Blockchain Corp. »

Long Blockchain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRAY

Cray

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Earnings
Cray sees FY17 revenue about $390M, consensus $399.96M »

Cray announced selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LNG

Cheniere Energy

$54.73

0.29 (0.53%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Cheniere Energy, Trafigura sign 15-year LNG sale and purchase agreement »

Cheniere Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Earnings
Ultra Clean reaffirms Q4 revenue view $240.0M-$250M, consensus $244.32M »

Sees Q4 operating margins…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PX

Praxair

$164.15

0.34 (0.21%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Praxair expands hydrogen supply to Motiva Port Arthur, Texas refinery »

Praxair, Inc. has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

, INCY

Incyte

$94.07

1.01 (1.09%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Downgrade
Concert Pharmaceuticals, Incyte rating change  »

Concert Pharmaceuticals…

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

INCY

Incyte

$94.07

1.01 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Recommendations
MGM Resorts, Las Vegas Sands, Wynn Resorts, Melco Resorts & Entertainment analyst commentary  »

Morgan Stanley raises…

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

WYNN

Wynn Resorts

$165.54

3.04 (1.87%)

MLCO

Melco Resorts & Entertainment

$27.01

-0.21 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.